Introduction to Antibody-Drug Conjugates

Area of Science:

• Biopharmaceutical development
• Drug discovery and delivery
• Antibody engineering

Background:

• Antibody-drug conjugates (ADCs) combine monoclonal antibodies with potent small molecule drugs via linkers.
• While primarily used for cancer, ADCs hold significant therapeutic potential for various diseases.
• The field has seen substantial progress in antibody discovery, bioengineering, and formulation.

Purpose of the Study:

• To provide a comprehensive overview of ADC biology, chemistry, and biophysical properties.
• To summarize current advancements and challenges in ADC development, focusing on conjugation, linker-payload chemistry, and drug-antibody ratio (DAR).
• To explore future innovations and potential for ADCs in non-oncology therapeutic areas.

Main Methods:

• Review of existing literature on antibody-drug conjugates.
• Analysis of components including monoclonal antibodies, linkers, and payloads.
• Discussion of product development, resistance mechanisms, and future perspectives.

Main Results:

• Ten ADCs are FDA-approved, with over 90 in global clinical development.
• Key areas of focus include antibody conjugation strategies, linker-payload chemistry, novel payload classes, and optimizing DAR.
• Lessons learned from oncology ADC development inform strategies for broader therapeutic applications.

Conclusions:

• ADCs represent a rapidly evolving class of therapeutics with expanding applications.
• Continued innovation in ADC design and development is crucial for unlocking their full potential across diverse diseases.
• Addressing resistance mechanisms and exploring new therapeutic indications are key future directions.